Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07008378 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

A Phase 1 study of Multiple Sclerosis, sponsored by Genentech.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT07008378 is a Phase 1 study of Multiple Sclerosis that is actively recruiting participants, run by Genentech. The registered enrollment target is 60 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07008378, a Phase 1 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

Conditions Studied

Multiple Sclerosis

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • BIOLOGICAL P-CD19CD20-ALLO1 Cells

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-15
Est. Completion 2032-08-31
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07008378

The ClinicalTrials.gov registry entry for NCT07008378 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT07008378 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT07008378 about?

NCT07008378 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis". This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

What is the current status of trial NCT07008378?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-10-15. Estimated completion is 2032-08-31.

What conditions does trial NCT07008378 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT07008378?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), P-CD19CD20-ALLO1 Cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT07008378?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07008378 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.